SRPT
Sarepta Therapeutics, Inc.
$15.78
+0.06%
$1.7B
No data for this timeframe.
Vol
Market Cap$1.7B
Cap SizeSmall Cap
Analyst ConsensusHold (39%)
Inst. Holders50 funds
Inst. Value$1.7B
Inst. Activity19 buys / 15 sells
Insider Activity0B / 1S
Insider Net $-$123.2K
Reddit Sentiment57° Neutral
SEC Reports4
Recent Activity
Jun 16, 2026
short_volume
Short Volume: SRPT — 55.6% short (0.4M / 0.8M)
Short: 436,427 | Exempt: 539 | TRF Vol: 784,767 | Short Ratio: 55.6% | Off-exchange volume (dark poo
Jun 11, 2026
SEC
An institutional cluster in SRPT shows 6 buyers (adding $99M) and 5 sellers (reducing $102.8M) in Q3 2025, resulting in
INST-CLUSTER — Impact 4/10
Jun 4, 2026
SEC
Sarepta Therapeutics held its 2026 annual meeting on June 4, 2026. Stockholders approved the new 2026 Equity Incentive P
8-K — Impact 3/10
Jun 4, 2026
Insider
Chambers Michael Andrew was granted 16,875 shares
Director
Jun 4, 2026
Insider
Barry Richard was granted 16,875 shares
Director
Jun 4, 2026
Insider
Nicaise Claude was granted 16,875 shares
Director
Apr 24, 2026
SEC
Sarepta Therapeutics filed a definitive proxy statement (DEFA14A) for its annual shareholder meeting, which includes rou
DEFA14A — Impact 3/10
Inst.
FIRST TRUST ADVISORS LP — DOUBLED
4,135,788 shares ($90.0M)
Price Targets
$22.00
+39.4% upside
Strong Buy
Current $15.78
Low $5.00
Median $20.00
High $38.00
23 analysts
$5.00
$38.00
Analyst Ratings
7Strong Buy
6Buy
15Hold
4Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 16, 2026 | HC Wainwright & Co. | REITERATE | Sell → Sell |
| Mar 26, 2026 | Citigroup | MAINTAIN | Sell → Sell |
| Mar 26, 2026 | Needham | REITERATE | Underperform → Underperform |
| Mar 19, 2026 | Oppenheimer | REITERATE | Outperform → Outperform |
| Mar 13, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.49 ▼ -55.5% | $0.11 — $0.79 | -76% YoY | 9 |
| Next Q | $0.50 ▼ -18.1% | $0.16 — $0.76 | 481% YoY | 9 |
| Current FY | $4.83 ▲ +20.9% | $3.45 — $6.30 | 196% YoY | 12 |
| Next FY | $2.73 ▼ -9.3% | $0.98 — $5.22 | -44% YoY | 12 |
Latest Reports
MIXED
INST-CLUSTER
4/10
An institutional cluster in SRPT shows 6 buyers (adding $99M) and 5 sellers (reducing $102.8M) in Q3 2025, resulting in
Jun 11, 2026
NEUTRAL
8-K
3/10
Sarepta Therapeutics held its 2026 annual meeting on June 4, 2026. Stockholders approved the new 2026 Equity Incentive P
Jun 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $321.1M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $144.5M | — |
| STATE STREET CORP | $143.9M | — |
| TWO SIGMA INVESTMENTS, LP | $99.9M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $99.6M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Chambers Michael | A | $0.00 |
| Jun 4, 2026 | Barry Richard | A | $0.00 |
| Jun 4, 2026 | Nicaise Claude | A | $0.00 |
| Jun 4, 2026 | Connelly Deirdre | A | $0.00 |
| Jun 4, 2026 | BEHRENS M | A | $0.00 |
Reddit Sentiment
57°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $1.7B total value (78,231,412 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 19 institutions added/increased vs 15 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 14,755,277 | $321.1M | 18.9% | — |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6,640,692 | $144.5M | 8.5% | — |
| 3 | STATE STREET CORP | 6,613,314 | $143.9M | 8.5% | — |
| 4 | TWO SIGMA INVESTMENTS, LP | 4,593,195 | $99.9M | 5.9% | — |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 4,578,235 | $99.6M | 5.9% | — |
| 6 | FIRST TRUST ADVISORS LP | 4,135,788 | $90.0M | 5.3% | DOUBLED +107.6% |
| 7 | RA CAPITAL MANAGEMENT, L.P. | 3,902,596 | $84.9M | 5.0% | NEW |
| 8 | Erste Asset Management GmbH | 2,968,945 | $61.3M | 3.6% | — |
| 9 | MORGAN STANLEY | 2,596,993 | $56.5M | 3.3% | ADD +35.8% |
| 10 | BANK OF AMERICA CORP /DE/ | 2,145,926 | $46.7M | 2.7% | ADD +26.6% |
| 11 | FEDERATED HERMES, INC. | 1,786,021 | $38.9M | 2.3% | ADD +36.0% |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 1,665,078 | $36.2M | 2.1% | ADD +43.6% |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,640,600 | $35.7M | 2.1% | — |
| 14 | LMR Partners LLP | 1,422,800 | $31.0M | 1.8% | TRIM -51.6% |
| 15 | CITADEL ADVISORS LLC | 1,304,700 | $28.4M | 1.7% | — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,280,600 | $27.9M | 1.6% | — |
| 17 | CANADA PENSION PLAN INVESTMENT BOARD | 1,242,800 | $27.0M | 1.6% | DOUBLED +258.3% |
| 18 | CITIGROUP INC | 1,147,648 | $25.0M | 1.5% | — |
| 19 | GOLDMAN SACHS GROUP INC | 1,078,252 | $23.5M | 1.4% | — |
| 20 | Connor, Clark & Lunn Investment Management Ltd. | 1,019,951 | $22.2M | 1.3% | TRIM -38.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FIRST TRUST ADVISORS LP | DOUBLED | 1,992,577 | 4,135,788 | +107.6% | $90.0M | 2026-Q1 |
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 3,902,596 | — | $84.9M | 2026-Q1 |
| MORGAN STANLEY | ADD | 1,912,635 | 2,596,993 | +35.8% | $56.5M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,694,590 | 2,145,926 | +26.6% | $46.7M | 2026-Q1 |
| FEDERATED HERMES, INC. | ADD | 1,313,313 | 1,786,021 | +36.0% | $38.9M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,159,578 | 1,665,078 | +43.6% | $36.2M | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | DOUBLED | 346,829 | 1,242,800 | +258.3% | $27.0M | 2026-Q1 |
| Legal & General Group Plc | DOUBLED | 264,457 | 866,743 | +227.7% | $18.9M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 143,493 | 725,068 | +405.3% | $15.8M | 2026-Q1 |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | NEW | — | 560,150 | — | $12.2M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 878,393 | 432,535 | -50.8% | $9.4M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 91,619 | 392,044 | +327.9% | $8.5M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 458,148 | 336,736 | -26.5% | $7.3M | 2026-Q1 |
| Trexquant Investment LP | ADD | 178,343 | 323,928 | +81.6% | $7.0M | 2026-Q1 |
| Cerity Partners LLC | TRIM | 212,316 | 149,850 | -29.4% | $3.3M | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 299,415 | 136,572 | -54.4% | $3.0M | 2026-Q1 |
| GROUP ONE TRADING LLC | TRIM | 140,774 | 99,915 | -29.0% | $2.2M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | TRIM | 235,021 | 103,005 | -56.2% | $2.1M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 41,921 | 56,539 | +34.9% | $1.2M | 2026-Q1 |
| HSBC HOLDINGS PLC | ADD | 33,548 | 55,549 | +65.6% | $1.2M | 2026-Q1 |
| Gotham Asset Management, LLC | NEAR_EXIT | 221,730 | 47,552 | -78.6% | $1.0M | 2026-Q1 |
| NORDEA INVESTMENT MANAGEMENT AB | TRIM | 63,317 | 38,451 | -39.3% | $822.1K | 2026-Q1 |
| &PARTNERS | TRIM | 112,446 | 37,444 | -66.7% | $814.8K | 2026-Q1 |
| Brevan Howard Capital Management LP | DOUBLED | 11,807 | 33,170 | +180.9% | $721.8K | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 1,159 | 25,949 | +2138.9% | $564.6K | 2026-Q1 |
12 unique insiders with 26 transactions. Net insider value: -$123.2K ($0.00 bought, $123.2K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Chambers Michael Andrew | Director | AWARD | 16,875 | — | — |
| Jun 4, 2026 | Barry Richard | Director | AWARD | 16,875 | — | — |
| Jun 4, 2026 | Nicaise Claude | Director | AWARD | 16,875 | — | — |
| Jun 4, 2026 | Connelly Deirdre P | Director | AWARD | 16,875 | — | — |
| Jun 4, 2026 | BEHRENS M KATHLEEN | Director | AWARD | 16,875 | — | — |
| Jun 4, 2026 | Wigzell Hans Lennart Rudolf | Director | AWARD | 16,875 | — | — |
| Jun 4, 2026 | Mayo Stephen | Director | AWARD | 16,875 | — | — |
| Jun 4, 2026 | Boor Kathryn Jean | Director | AWARD | 16,875 | — | — |
| Mar 12, 2026 | Mayo Stephen | Director | SELL | 7,239 | $17.02 | $123.2K |
| Mar 11, 2026 | Rothfuss Cristin | EVP, General Counsel | TAX W/H | 974 | $17.03 | $16.6K |
| Mar 11, 2026 | Rodino-Klapac Louise | President, R&D and Tech Ops | TAX W/H | 948 | $17.03 | $16.1K |
| Mar 11, 2026 | Estepan Ian Michael | Chief Operating Officer | TAX W/H | 1,097 | $17.03 | $18.7K |
| Mar 11, 2026 | Wong Ryan Ho-Yan | Chief Financial Officer | TAX W/H | 256 | $17.03 | $4.4K |
| Mar 9, 2026 | Estepan Ian Michael | Chief Operating Officer | TAX W/H | 1,036 | $16.95 | $17.6K |
| Mar 9, 2026 | Rodino-Klapac Louise | President, R&D and Tech Ops | TAX W/H | 504 | $16.95 | $8.5K |
| Mar 9, 2026 | Rothfuss Cristin | EVP, General Counsel | TAX W/H | 484 | $16.95 | $8.2K |
| Mar 9, 2026 | Wong Ryan Ho-Yan | Chief Financial Officer | TAX W/H | 162 | $16.95 | $2.7K |
| Mar 2, 2026 | Wong Ryan Ho-Yan | Chief Financial Officer | TAX W/H | 450 | $16.20 | $7.3K |
| Mar 2, 2026 | Estepan Ian Michael | Chief Operating Officer | TAX W/H | 3,301 | $16.20 | $53.5K |
| Mar 2, 2026 | Rothfuss Cristin | EVP, General Counsel | TAX W/H | 408 | $16.20 | $6.6K |
| Mar 2, 2026 | Rodino-Klapac Louise | President, R&D and Tech Ops | TAX W/H | 3,718 | $16.20 | $60.2K |
| Mar 1, 2026 | Estepan Ian Michael | Chief Operating Officer | EXERCISE | 8,125 | — | — |
| Mar 1, 2026 | Rodino-Klapac Louise | President, R&D and Tech Ops | EXERCISE | 8,125 | — | — |
| Feb 26, 2026 | Estepan Ian Michael | Chief Operating Officer | EXERCISE | 2,069 | $13.71 | $28.4K |
| Feb 25, 2026 | Estepan Ian Michael | Chief Operating Officer | AWARD | 1,875 | — | — |
| Feb 25, 2026 | Rodino-Klapac Louise | President, R&D and Tech Ops | AWARD | 1,875 | — | — |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 2 mixed, 2 neutral. Avg impact: 4.3/10.
MIXED
INST-CLUSTER
4/10
An institutional cluster in SRPT shows 6 buyers (adding $99M) and 5 sellers (reducing $102.8M) in Q3
Jun 11, 2026
NEUTRAL
8-K
3/10
Sarepta Therapeutics held its 2026 annual meeting on June 4, 2026. Stockholders approved the new 202
Jun 4, 2026
NEUTRAL
DEFA14A
3/10
Sarepta Therapeutics filed a definitive proxy statement (DEFA14A) for its annual shareholder meeting
Apr 24, 2026
MIXED
8-K
7/10
Sarepta Therapeutics reported mixed financial results for 2025, with full-year revenue growing 16% t
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Sell (39% buy). Based on 33 analysts: 7 strong buy, 6 buy, 15 hold, 4 sell, 1 strong sell.
Analyst Price Targets
$22.00 mean target
+39.4% upside
Strong Buy (3.00)
$5.00 Low
$38.00 High
| Metric | Value |
|---|---|
| Current Price | $15.78 |
| Target Low | $5.00 |
| Target Mean | $22.00 |
| Target Median | $20.00 |
| Target High | $38.00 |
| # Analysts | 23 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.49 | $0.11 | $0.79 | -75.8% | -55.5% | 1↑ 8↓ | $0.4B | -40.2% | 9 |
| Next Q 2026-09-30 |
$0.50 | $0.16 | $0.76 | 481.3% | -18.1% | 4↑ 5↓ | $0.4B | -6.9% | 9 |
| Current FY 2026-12-31 |
$4.83 | $3.45 | $6.30 | 195.6% | +20.9% | 9↑ 3↓ | $1.8B | -16.4% | 12 |
| Next FY 2027-12-31 |
$2.73 | $0.98 | $5.22 | -43.6% | -9.3% | 5↑ 7↓ | $1.4B | -22.5% | 12 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.488 | |
| 7d ago | $0.505 | -0.017 |
| 30d ago | $1.097 | -0.608 |
| 60d ago | $1.105 | -0.616 |
| 90d ago | $0.842 | -0.354 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 16, 2026 | HC Wainwright & Co. | REITERATE | Sell | Sell |
| Mar 26, 2026 | Citigroup | MAINTAIN | Sell | Sell |
| Mar 26, 2026 | Needham | REITERATE | Underperform | Underperform |
| Mar 19, 2026 | Oppenheimer | REITERATE | Outperform | Outperform |
| Mar 13, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 10, 2026 | Citigroup | MAINTAIN | Sell | Sell |
| Mar 2, 2026 | HC Wainwright & Co. | REITERATE | Sell | Sell |
| Feb 27, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 27, 2026 | HC Wainwright & Co. | REITERATE | Sell | Sell |
| Jan 23, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Jan 14, 2026 | HC Wainwright & Co. | REITERATE | Sell | Sell |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 6 | 15 | 4 | 1 | 39% | |
| May 1, 2026 | 7 | 6 | 15 | 4 | 1 | 39% | |
| Apr 1, 2026 | 7 | 6 | 15 | 4 | 1 | 39% | |
| Mar 1, 2026 | 6 | 6 | 16 | 4 | 1 | 36% | |
| Feb 1, 2026 | 6 | 6 | 16 | 4 | 1 | 36% | |
| Jan 1, 2026 | 6 | 6 | 16 | 4 | 1 | 36% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
57°
Neutral
Bearish
Neutral
Bullish
3 mentions
2 bullish
1 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 7, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 7, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 15, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
$SRPT just dropped their Q1 earnings...
▲ 1
💬 1
⚡ 0.5
SRPT is going to $15 before it goes to $30
▲ 1
💬 0
⚡ 0.5
Jun 16, 2026
short_volume
Short Volume: SRPT — 55.6% short (0.4M / 0.8M)
Short: 436,427 | Exempt: 539 | TRF Vol: 784,767 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
Jun 12, 2026
short_volume
Short Volume: SRPT — 61.0% short (0.4M / 0.7M)
Short: 428,181 | Exempt: 0 | TRF Vol: 702,039 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
Jun 11, 2026
short_volume
Short Volume: SRPT — 66.0% short (0.7M / 1.0M)
Short: 657,038 | Exempt: 5 | TRF Vol: 995,932 | Short Ratio: 66.0% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: SRPT — 61.8% short (0.6M / 1.0M)
Short: 612,464 | Exempt: 1,681 | TRF Vol: 991,130 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: SRPT — 62.3% short (0.6M / 1.0M)
Short: 622,526 | Exempt: 151 | TRF Vol: 999,674 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: SRPT — 57.1% short (0.5M / 1.0M)
Short: 546,144 | Exempt: 3,322 | TRF Vol: 956,374 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: SRPT — 60.0% short (0.5M / 0.8M)
Short: 507,994 | Exempt: 10 | TRF Vol: 847,040 | Short Ratio: 60.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: SRPT — 66.1% short (0.9M / 1.3M)
Short: 874,138 | Exempt: 3,543 | TRF Vol: 1,321,848 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: SRPT — 55.7% short (0.6M / 1.0M)
Short: 555,215 | Exempt: 1,778 | TRF Vol: 995,976 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: SRPT — 66.2% short (0.8M / 1.2M)
Short: 806,609 | Exempt: 0 | TRF Vol: 1,218,231 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
May 29, 2026
ftd
FTD: SRPT — 150,468 shares ($2.6M) failed to deliver
Settlement: 20260529, Price: $17.30, FTD Value: $2,603,096.4, SAREPTA THERAPEUTICS INC COM S
May 26, 2026
short_volume
Short Volume: SRPT — 55.0% short (0.6M / 1.0M)
Short: 576,918 | Exempt: 1,045 | TRF Vol: 1,048,911 | Short Ratio: 55.0% | Off-exchange volume (dark pool + OTC)
May 25, 2026
dark_pool
Dark Pool: SRPT — 2.7M shares, 51,922 trades
Week starting 2026-05-25. Total ATS volume: 2,671,834 shares across 51,922 trades.
May 22, 2026
short_volume
Short Volume: SRPT — 59.5% short (0.4M / 0.7M)
Short: 408,559 | Exempt: 33 | TRF Vol: 686,099 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: SRPT — 2.5M shares, 52,256 trades
Week starting 2026-05-18. Total ATS volume: 2,460,950 shares across 52,256 trades.